Sinclair’s FY trading update indicates revenue for the period of £37.8m, ahead of our £35.4m estimate. Cash at period-end was slightly below our expectations at £16.8m vs. our £18.5m forecast. Sales of the five key products are in line or slightly ahead of estimates. Importantly, the early indications are positive for the US rollout of Silhouette Instalift™ with practitioner training ahead of schedule. Overall a positive trading update: we reiterate our Buy recommendation and 42p target price. ....
17 Jan 2017
N+1 Singer - Sinclair Pharma - FY trading update: revenue ahead of estimates
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Sinclair Pharma - FY trading update: revenue ahead of estimates
Sinclair Pharma (SPH:LON) | 0 0 0.6% | Mkt Cap: 111.5m
- Published:
17 Jan 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
Sinclair’s FY trading update indicates revenue for the period of £37.8m, ahead of our £35.4m estimate. Cash at period-end was slightly below our expectations at £16.8m vs. our £18.5m forecast. Sales of the five key products are in line or slightly ahead of estimates. Importantly, the early indications are positive for the US rollout of Silhouette Instalift™ with practitioner training ahead of schedule. Overall a positive trading update: we reiterate our Buy recommendation and 42p target price. ....